Cancer Monoclonal Antibodies Market: By Application, By Type of Antibody, By Conjugation ), By Distribution Channel and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Cancer Monoclonal Antibodies Market Size, Share, Growth, Trends, and Global Industry Analysis: By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Other), By Type of Antibody (Murine Antibodies, Humanized Antibodies, Chimeric Antibodies), By Conjugation (Immunocytokines, Immunoliposome, Radioimmunotherapy, Antibody Directed Enzyme Prodrug Therapy(ADEPT)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacie, Online Pharmacies) and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Cancer Monoclonal Antibodies Market size was valued at US$ 54.2 billion in 2023 and is poised to grow at a CAGR of 11.8% from 2024-2030. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of a cancer cell when the antibody binds to an antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process.

Due to its specificity, monoclonal antibodies have the least adverse effects than other cancer-treating drugs. Currently market is witnessing significant growth. Targeted and combination therapy drugs are leading in the market. Several market players collaborating to develop antibody drugs to treat various types of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for a new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function-modulating antibodies against undisclosed membrane protein targets. Academic institutions and organizations like the National Institute of Health (USA), the National Cancer Institute (USA), and many others are collaborating and participating in cancer research and awareness activities.

Key Developments

  • In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology's tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

summary download arrow Download Free Sample

Global Cancer Monoclonal Antibodies Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

11.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Cancer Monoclonal Antibodies Market Dynamics

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies.

Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue ofcancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of market.

Global Cancer Monoclonal Antibodies Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 54.2 billion

Market CAGR

11.8%

By Application

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain cancer
  • Colorectal Cancer
  • Others

By Type of Antibody

  • Murine Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies

By Conjugation

  • Immunocytokines
  • Immunoliposome
  • Radioimmunotherapy
  • Antibody Directed Enzyme Prodrug Therapy(ADEPT)

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The cancer monoclonal antibodies market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global cancer monoclonal antibodies market size was valued at US$ 54.2 billion in 2023 and is projected to grow at a CAGR of 11.8% from 2024 to 2030.

Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi  (France)

North America is the fastest-growing region for cancer monoclonal antibodies market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Cancer Monoclonal Antibodies Market Introduction 
2.1.Global Cancer Monoclonal Antibodies Market  - Taxonomy
2.2.Global Cancer Monoclonal Antibodies Market  - Definitions
2.2.1.Type of Antibody
2.2.2.Application
2.2.3.Conjugation
2.2.4.Distribution channel
2.2.5.Region
3.Global Cancer Monoclonal Antibodies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Cancer Monoclonal Antibodies Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Cancer Monoclonal Antibodies Market  By Type of Antibody, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Murine Antibodies
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Humanized Antibodies
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Chimeric Antibodies
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Cancer Monoclonal Antibodies Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Breast Cancer
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Blood Cancer
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Liver Cancer
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Brain cancer
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Colorectal Cancer
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Cancer Monoclonal Antibodies Market  By Conjugation, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Immunocytokines
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Immunoliposome
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Radioimmunotherapy
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Cancer Monoclonal Antibodies Market  By Distribution channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Cancer Monoclonal Antibodies Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type of Antibody Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Murine Antibodies
10.1.2.Humanized Antibodies
10.1.3.Chimeric Antibodies
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Breast Cancer
10.2.2.Blood Cancer
10.2.3.Liver Cancer
10.2.4.Brain cancer
10.2.5.Colorectal Cancer
10.2.6.Others
10.3.  Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Immunocytokines
10.3.2.Immunoliposome
10.3.3.Radioimmunotherapy
10.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT)
10.4.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type of Antibody Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Murine Antibodies
11.1.2.Humanized Antibodies
11.1.3.Chimeric Antibodies
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Breast Cancer
11.2.2.Blood Cancer
11.2.3.Liver Cancer
11.2.4.Brain cancer
11.2.5.Colorectal Cancer
11.2.6.Others
11.3.  Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Immunocytokines
11.3.2.Immunoliposome
11.3.3.Radioimmunotherapy
11.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT)
11.4.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type of Antibody Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Murine Antibodies
12.1.2.Humanized Antibodies
12.1.3.Chimeric Antibodies
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Breast Cancer
12.2.2.Blood Cancer
12.2.3.Liver Cancer
12.2.4.Brain cancer
12.2.5.Colorectal Cancer
12.2.6.Others
12.3.  Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Immunocytokines
12.3.2.Immunoliposome
12.3.3.Radioimmunotherapy
12.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT)
12.4.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type of Antibody Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Murine Antibodies
13.1.2.Humanized Antibodies
13.1.3.Chimeric Antibodies
13.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Breast Cancer
13.2.2.Blood Cancer
13.2.3.Liver Cancer
13.2.4.Brain cancer
13.2.5.Colorectal Cancer
13.2.6.Others
13.3.  Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Immunocytokines
13.3.2.Immunoliposome
13.3.3.Radioimmunotherapy
13.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT)
13.4.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Type of Antibody Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Murine Antibodies
14.1.2.Humanized Antibodies
14.1.3.Chimeric Antibodies
14.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Breast Cancer
14.2.2.Blood Cancer
14.2.3.Liver Cancer
14.2.4.Brain cancer
14.2.5.Colorectal Cancer
14.2.6.Others
14.3.  Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Immunocytokines
14.3.2.Immunoliposome
14.3.3.Radioimmunotherapy
14.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT)
14.4.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Merck & Co. Inc.
15.2.2.F. Hoffmann-La Roche AG
15.2.3.Spectrum Pharmaceuticals
15.2.4.Eli Lilly and Company
15.2.5.Amgen Inc.
15.2.6.Bristol-Meyer Squibb
15.2.7.Sanofi
15.2.8.AstraZeneca
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Merck & Co. Inc.
  • F. Hoffmann-La Roche AG
  • Spectrum Pharmaceuticals
  • Eli Lilly and Company
  • Amgen Inc.
  • Bristol-Meyer Squibb
  • Sanofi
  • AstraZeneca

Related Industry Reports

Bispecific Antibodies Market

Monoclonal Antibody Therapeutics Market

Her2 Antibodies Market

Global Ovarian Cancer Treatment Market